Skip to main content

Table 1 Baseline characteristics of 66 subjects with PAH on inhaled prostacyclin

From: Treatment satisfaction is associated with improved quality of life in patients treated with inhaled treprostinil for pulmonary arterial hypertension

Characteristic Baseline (n = 66)
Age, mean (range), yr 49 (18 – 74)
Male : Female, n (%) 15 (23) : 51 (77)
White* 58 (88)
PAH etiology, n (%)
  Idiopathic/heritable 33 (50)
  Collagen vascular disease 13 (20)
  Congenital heart disease 17 (26)
  HIV 3 (5)
Background PAH therapy, n (%)
  Endothelin receptor antagonist 56 (85)
  Phosphodiesterase-5 inhibitor 46 (70)
  Both 39 (59)
  None 3 (5)
WHO functional class, n (%)
  II 38 (58)
  III 28 (42)
6-minute walk distance, mean ± SD, m 395 ± 79
Borg dypnea score, mean ± SD 3.4 ± 2.1
Iloprost dose, n (%)
  2.5 μg 4 (6)
  5.0 μg 62 (94)
Iloprost frequency
  < 6 times per day 25 (38)
  ≥ 6 times per day 41 (62)
  1. * n = 58 (8 missing).